{
  "docId": "019de074-05b7-71fd-bc3c-27f1b7be8924",
  "docSlug": "c3cb552ef3a6b077a714c97117e1fe86",
  "documentTitle": "Mink Therapeutics | Investor Day Presentation Deck | 92 slides",
  "authorId": "mink-therapeutics",
  "authorName": "MiNK Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 92,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "before_after",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 15,
  "notes": "The chart displays patient outcomes over time, with dots indicating progression and bars indicating stable disease.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-05b7-71fd-bc3c-27f1b7be8924/31",
  "deckHref": "/decks/019de074-05b7-71fd-bc3c-27f1b7be8924",
  "deckJsonHref": "/decks/019de074-05b7-71fd-bc3c-27f1b7be8924.json",
  "deckAnchorHref": "/decks/019de074-05b7-71fd-bc3c-27f1b7be8924#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.43,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "chart",
      "text": "Reduction in Target and Non-Target Lesions in Heavily Pre-treated Patients",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a6a2337e-eb9e-4135-a0ca-7cd8df649dcd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.52,
        "y": 0.28
      },
      "kind": "list",
      "text": "Reduction of target and non-target lesions or disease stabilization in patients treated with agenT-797 alone (27%) or in combination with pembro/nivo (66%). Disease stabilization observed after failure of SOC and progression on checkpoint inhibitors.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "621461de-5cce-4245-b1de-4ec4f1e280fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.52,
        "y": 0.5
      },
      "kind": "table",
      "text": "Cancer, Dose Level, # Prior Lines, Response (weeks)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a465e5ea-00b3-4325-9d2f-82da49a6b0f5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "agenT-797 Shows Early Signs of Clinical Activity in Solid Tumors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ace3ccbc-9916-472e-84cf-298e76eee6fd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "f630c83c-723a-4f73-a773-d2133883b6ff",
      "evidence": "Reduction of target and non-target lesions or disease stabilization in patients treated with agenT-797 alone (27%) or in combination with pembro/nivo (66%).",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 35,
      "from": 23,
      "beatId": "3ca2588f-ae86-4809-9434-ea06292b2cdd",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence",
      "beatSlug": "evidence",
      "evidence": "The presentation provides preclinical and clinical data supporting iNKT cells' potential",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 35,
      "from": 23,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "d3a14978-bf9f-4a75-b0e8-87c8ef56ddbf",
      "evidence": "The presentation uses before-after comparisons to show iNKT cells' potential",
      "position": 1,
      "objective": "Illustrating the benefits of iNKT cells",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.7,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}